Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 3/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 3/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27794375 | 1.00 | CES1 (0.50) | CES1SRCTSHRTDP1HSD17B10 | |
| SCHEMBL27980842 | 1.00 | CES1 (0.50) | CES1SRCTSHRTDP1HSD17B10 | |
| SCHEMBL28276721 | 0.87 | CES1 (0.58) | CES1SRCTSHRTDP1HSD17B10 | |
| SCHEMBL27961634 | 0.84 | CES1 (0.51) | CES1SRCTSHRTDP1HSD17B10 | |
| SCHEMBL28241325 | 0.83 | TSHR (0.45) | CES1SRCTSHRTDP1HSD17B10 | |
| SCHEMBL32101 | 0.82 | CES1 (0.56) | CES1SRCTSHRTDP1HSD17B10 | |
| SCHEMBL9718709 | 0.77 | CES1 (0.55) | CES1SRCTSHRTDP1HSD17B10 | |
| SCHEMBL28032281 | 0.76 | SRC (0.48) | CES1SRCTSHRTDP1HSD17B10 | |
| SCHEMBL50469 | 0.76 | CES1 (0.58) | CES1SRCTSHRTDP1HSD17B10 | |
| SCHEMBL4955716 | 0.76 | CES1 (0.46) | CES1SRCTSHRTDP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115960036-B | Preparation method of (R) -3-aminopiperidine dihydrochloride | 大连双硼医药化工有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-118420658-B | Preparation method of chiral triazine compound | 天津辰欣药物研究有限公司 | 2024-09-20 | — | — | CN | claimed |
| CN-118420658-A | Preparation method of chiral triazine compound | 天津辰欣药物研究有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-114573503-B | Method for preparing octreotide intermediate | 浙江天宇药业股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-114644636-B | Method for preparing tofacitinib key intermediate | 江苏恒沛药物科技有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-121318964-A | Resolution method of non-nelidone racemate | 上海启讯医药科技有限公司 | 2026-01-13 | — | — | CN | disclosed |
| CN-116986962-B | Method for biphase identification extraction resolution of ofloxacin chiral drug | 华东理工大学 | 2025-08-12 | — | — | CN | disclosed |
| CN-115960036-B | Preparation method of (R) -3-aminopiperidine dihydrochloride | 大连双硼医药化工有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-115960036-B | Preparation method of (R) -3-aminopiperidine dihydrochloride | 大连双硼医药化工有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-118420658-B | Preparation method of chiral triazine compound | 天津辰欣药物研究有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118420658-A | Preparation method of chiral triazine compound | 天津辰欣药物研究有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118108612-A | Preparation method of high-purity L-phenylephrine hydrochloride | 南京海融制药有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-106699712-A | Vorapaxar intermediate and preparation method thereof | 上海博志研新药物技术有限公司 | 2017-05-24 | — | — | CN | disclosed |
| CN-104284895-B | Nitrogenous dicyclic aromatic heterocyclic compounds | 安斯泰来制药株式会社 | 2016-08-31 | — | — | CN | disclosed |
| US-8748610-B2 | Compounds as TRPV1 antagonists, pharmaceutical compositions and medical uses thereof | FL THERAPEUTICS LLC (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120184509-A1 | Compounds as TRVP1 Blockers, Pharmaceutical Compositions and Medical Uses Thereof | ZHUHAI BEIHAI BIOTECH CO., LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
| CN-102076338-A | Diaryl ureas for the treatment of heart failure | BAYER SCHERING PHARMA AG | 2011-05-25 | — | — | CN | disclosed |
| CN-1671380-B | Broadspectrum 2-amino-benzothiazole sulfonamide HIV protease inhibitors | TIBOTEC PHARM LTD | 2010-05-26 | — | — | CN | disclosed |
| CN-1953751-A | Combination of substituted 1-phenyl-1, 5-dihydro-pyrido- [3, 2-B ] indol-2-ones and other HIV inhibitors | TIBOTEC PHARM LTD (IE) | 2007-04-25 | — | — | CN | disclosed |
| CN-1671380-A | Broadspectrum 2-amino-benzothiazole sulfonamide HIV protease inhibitors | TIBOTEC PHARM LTD (IE) | 2005-09-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184509-A1 | Compounds as TRVP1 Blockers, Pharmaceutical Compositions and Medical Uses Thereof | TRPV1, TRPV4, TRPV3 | CES1 1847/4885SRC 3352/4885TSHR 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.